[Federal Register Volume 90, Number 113 (Friday, June 13, 2025)]
[Notices]
[Pages 25080-25081]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-10809]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Rapid Response Partnership Vehicle
Notice is hereby given that, on April 8, 2025, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership
Vehicle (``RRPV'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Fisher BioServices, Inc., Rockville, MD; Landmark
Vaccines, Ltd., Loughborough, UNITED KINGDOM; Rx Bandz, Locust Valley,
NY; Zeteo Tech, Inc., Sykesville, MD; BioNet-Asia Co., Ltd, Bangkok,
KINGDOM OF THAILAND; EmitBio, Inc., Morrisville, NC; Matisse
Pharmaceuticals, B.V., Geleen, KINGDOM OF THE NETHERLANDS; National
Institute for Pharmaceutical Technology and Education, Inc.,
Minneapolis, MN; ProtonDx, Ltd., London, UNITED KINGDOM; BioVaxys
Technology Corp., Etobicoke, CANADA; Enplas, Santa Clara, CA; RHEAVITA
BV, Ghent, KINGDOM OF BELGIUM; Celltheon, Union City, CA; Chromatan,
Inc., Lower Gwynedd, PA; Cyrus Biotechnology, Seattle, WA; Eradivir,
Inc., West Lafayette, IN; InDevR, Inc., Boulder, CO; Kudo
Biotechnology, Inc., Needham, MA; Panoplia Laboratories, Inc.,
Cambridge, MA; The Regents of the University of California on behalf of
its Los Angeles campus, Los Angeles, CA; Meridian Medical Technologies
LLC, St. Louis, MO; Sarfez Pharmaceuticals, Inc., Vienna, VA; Tiba
Biotech LLC, Cambridge, MA; Ecolab, Inc., Philadelphia, PA; Unicorn
Biotechnologies, Inc., Newark, NJ; Zipcode Bio, Weston, MA; Acclinate,
Inc., Birmingham, AL; Klim-Loc Medical, Inc., Carbondale, CO; Primary
Diagnostics, Inc. dba Primary.Health, San Francisco, CA; Epitogenesis,
Inc., Virginia Beach, VA; Microbio, Ltd., Brisbane, COMMONWEALTH OF
AUSTRALIA; Aldevron LLC, Fargo, ND; BC3 Technologies, Inc., Baltimore,
MD; Genvax, Ames, IA; Maxim Biomedical, Inc., Rockville, MD; Piezo
Therapeutics, Inc., Atlanta, GA; Virtu, Inc., Leesburg, VA; Digital
Infuzion LLC, Rockville, MD; Neolixir, Ltd., Perth, AUSTRALIA; XCMR,
Inc., Narberth, PA; GenevationUS LLP, Sacramento, CA; Respana
Therapeutics, Inc., Philadelphia, PA; University of Louisiana at
Lafayette, Lafayette, LA; EriVan, Alachua, FL; President and Fellows of
Harvard College, Cambridge, MA; MedinCell, Inc., Jacou, FRENCH
REPUBLIC; Ambient Biosciences, Ann Arbor, MI; Antirna, Inc.,
Burlington, MA; Avid Bioservices, Inc., Tustin, CA; CMC
Pharmaceuticals, Inc., Solon, OH; FluGen, Inc., Madison, WI; Foundry,
Boston, MA; Nutrivert, Inc., Atlanta, GA; The United States
Pharmacopeial Convention, Inc., Rockville, MD; Particella, Inc., San
Francisco, CA; Ampulis, Inc., Berwyn, PA; Rozum Consulting, Newtown,
PA; Halomine, Inc. dba AvantGuard, Ithaca, NY; Luminary Labs LLC, New
York, NY; Pluri Biotech, Ltd., Haifa, STATE OF ISRAEL; Public Health
Vaccines LLC, Cambridge, MA; B&S Research, Inc., Embarress, MN; and
General Therapeutics, Inc., Gaithersburg, MD have been added as parties
to this venture.
Also, TFF Pharmaceuticals, Inc., Fort Worth, TX; Spring Discovery,
Inc., San Carlos, CA; Cue Health, Inc., San Diego, CA; and Deimos
Biosciences, San Francisco, CA have withdrawn as parties to this
venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and RRPV intends to file additional
written notifications disclosing all changes in membership.
On January 5, 2024, RRPV filed its original notification pursuant
to section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to section 6(b) of the Act on
April 16, 2024 (89 FR 26928).
The last notification was filed with the Department on January 16,
2025. The Department of Justice published a notice in the Federal
Register pursuant
[[Page 25081]]
to section 6(b) of the Act on February 28, 2025 (90 FR 10949).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2025-10809 Filed 6-12-25; 8:45 am]
BILLING CODE P